BioSpace News Archive

According to a recent BioSpace survey, 93% of respondents are open to a new job for the right opportunity. Are you one of the 93%? If so, keep your eyes open for those opportunities and don’t stop looking. You never know what may come your way!

The company indicated it was dropping LY2606368, prexasertib, a CHK1 drug in Phase II, and LY3023414, a PI3k/mTOR inhibitor that was also in Phase II.

Phoenix Tissue Repair, Inc. announced that the U.S. Food and Drug Administration has granted fast track designation for PTR-01, an investigational protein replacement therapy designed to treat recessive dystrophic epidermolysis bullosa.

Today, the American Urological Association (AUA), a leading global urology association, released a new joint clinical guideline with the Canadian Urological Association (CAU) and Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU), on the diagnosis and treatment of recurrent urinary tract infections (UTIs) in women.

The Wyoming, Michigan-based healthcare organization will partner with Glytec to provide patients an integrated model of technology-enabled glycemic management

Grand River Aseptic Manufacturing, Inc., a leading parenteral contract development and manufacturing organization, has implemented its fully-automated serialization and aggregation processes for commercial injectable drug products.

Akebia Therapeutics, Inc. announced plans to release its financial results for the first quarter ended March 31, 2019, on Thursday, May 9, 2019, before the opening of the financial markets.

Ocular Therapeutix, Inc announced that it has settled litigation with Mati Therapeutics, Inc., regarding alleged infringement of U.S. Patent 7,922,702.

20 abstracts will be presented during the AAN Annual Meeting 2019 to demonstrate EMD Serono’s commitment and clinical development program in multiple sclerosis

Breast health leader will highlight expanding portfolio for breast conserving surgery